2025-11-14T12:55:00-06:00 2024-12-31 390974031 WEGNER CPAS LLP 230 PARK AVE FL 3 NEW YORK NY 101690005 990 2024-01-01 825129481 GYNUITY HEALTH PROJECTS INC GYNU 2124481230 215 LEXINGTON AVENUE 1702 NEW YORK NY 10016 BEVERLY WINIKOFF PRESIDENT 2124481230 2025-11-14 1 1 YIGIT UCTUM CPA P01269549 2125511724 2025-11-11 2024 2025-03-06 01:10:19Z BEVERLY WINIKOFF 215 LEXINGTON AVENUE 1702 NEW YORK NY 10016 829790 0 X GYNUITY.ORG X 2018 DE GYNUITY'S APPROACH STARTS AT THE COMMUNITY LEVEL WHERE WE LISTEN TO WOMEN, PROVIDERS AND POLICYMAKERS, AND WORK WITH THEM TO CREATE SERVICES THAT ARE SAFE, OF HIGH QUALITY AND MORE PERSON-CENTERED. THROUGH CONVERSATIONS AND ACTIVE COLLABORATIONS WITH PARTNERS ON-THE GROUND, WE FILL EVIDENCE GAPS BY USING BASIC SCIENCE RESEARCH, CLINICAL RESEARCH, IMPLEMENTATION RESEARCH TO ACHIEVE PROOF OF CONCEPT FOR NEW MODELS OF CARE. WE USE THIS INFORMATION TO INFLUENCE CHANGE AND ADVOCATE FOR IMPROVEMENTS IN POLICY AND PRACTICE. 5 4 6 6 0 0 411062 821252 52013 2000 14597 6538 3321 0 480993 829790 0 0 0 0 954913 494826 0 0 47782 627326 441012 1582239 935838 -1101246 -106048 620039 353713 438697 278419 181342 75294 X GYNUITY HEALTH PROJECTS WORKS TO DEVELOP AND ADVOCATE FOR THE USE OF SCIENTIFIC, CLINICAL AND PROGRAMMATIC EVIDENCE IN REPRODUCTIVE AND MATERNAL HEALTH, ASSURING THAT EACH INDIVIDUAL BENEFITS FROM THE FRUITS OF MEDICAL SCIENCE AND TECHNOLOGY. 0 0 496493 0 2000 GYNUITY HEALTH PROJECTS IS AT THE FRONTLINE OF GLOBAL RESEARCH AND ADVOCACY EFFORTS TO EXPAND ACCESS TO MEDICATION ABORTION AND IMPROVE THE MANAGEMENT OF OBSTETRIC COMPLICATIONS. IN 2024, WE ORGANIZED A TECHNICAL MEETING OF ORGANIZATIONS ENGAGED IN MEDICATION ABORTION SERVICE DELIVERY, ADVOCACY, AND RESEARCH. BUILDING ON KEY LEARNINGS FROM OUR PROOF-OF-CONCEPT STUDY IN MEXICO EVALUATING USE OF ULIPRISTAL ACETATE (UPA) AS AN ALTERNATIVE TO MIFEPRISTONE FOR MEDICATION ABORTION, WE INITIATED NEW RESEARCH TO FURTHER ESTABLISH THE UTILITY OF UPA IN A COMBINED REGIMEN WITH MISOPROSTOL. ENROLLMENT BEGAN FOR A STUDY EVALUATING THE FEASIBILITY OF MEDICATION ABORTION SERVICES VIA TELEMEDICINE USING MISOPROSTOL ALONE IN ECUADOR AND FOR A STUDY IN MEXICO EXPLORING A NEW 'PERIOD PILLS' REGIMEN USED TO REGULATE MENSTRUATION WITHOUT PRIOR PREGNANCY CONFIRMATION. THIS YEAR, WE PUBLISHED SEVERAL NEW JOURNAL ARTICLES SUMMARIZING COMPLETED STUDIES, INCLUDING ONE IN THE UNITED STATES TESTING A NEW ONLINE PROGRAM TO DETERMINE ELIGIBILITY FOR MEDICATION ABORTION THAT USES A SELF-COMPLETED QUESTIONNAIRE, AND ANOTHER CONDUCTED IN PUBLIC SECTOR FACILITIES IN NEPAL EVALUATING THE POTENTIAL OF AN OUTPATIENT MODEL TO LIMIT INPATIENT CARE AND OVERNIGHT STAYS FOR SECOND TRIMESTER (13-18 WEEKS) MEDICATION INDUCTION. AT GYNUITY, WE PERFORM RESEARCH ON PROMISING MATERNAL HEALTH TECHNOLOGIES AND MODELS OF CARE SUITABLE FOR USE IN LOW-RESOURCE ENVIRONMENTS. IN 2024, WE PUBLISHED THE CLINICAL RESULTS FROM A RANDOMIZED TRIAL UNDERTAKEN IN CENTRAL INDIA CONFIRMING ORAL MISOPROSTOL ALONE AS AN EFFECTIVE OPTION FOR INDUCING LABOR IN PREGNANCIES COMPLICATED BY HYPERTENSION. WE CONTINUED TO ENGAGE STRATEGICALLY WITH PARTNERS AND LEADING HEALTH AUTHORITIES TO SHARE EVIDENCE FOR UPDATING GUIDELINES AND PRACTICES. 496493 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 7 0 6 1 0 0 0 0 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 0 1 1 0 NY X YELENA ELYUKIN 2124481230 215 LEXINGTON AVENUE 1702 NEW YORK NY 10016 BEVERLY WINIKOFF PRESIDENT 35.00 X X 170652 0 13601 GEORGE BROWN CHAIR 0.50 X X 0 0 0 ANN SCHUTT-AINE DIRECTOR 0.50 X 0 0 0 SILVINA RAMOS DIRECTOR 0.50 X 0 0 0 BARBARA CRANE DIRECTOR 0.50 X 0 0 0 PAMELA BARNES DIRECTOR (THRU JAN) 0.50 X 0 0 0 ANJU MALHOTRA DIRECTOR (THRU APRIL) 0.50 X 0 0 0 YELENA ELYUKIN TREASURER/SR. DIR. OF FINANCE AND ADMINISTRATION 35.00 X 94654 0 8512 JILL DUROCHER INTERIM SECRETARY/SENIOR DIRECTOR 24.50 X 70131 0 5810 335437 0 27923 1 0 1 0 0 821252 821252 TECHNICAL ASSISTANCE 541900 2000 2000 2000 6538 6538 829790 2000 0 6538 X 362435 149303 182668 30464 72634 27138 45467 29 5218 2116 2736 366 20311 8237 10650 1424 34228 13881 17948 2399 21089 21089 177358 174099 3259 10455 5548 4355 552 18007 7303 9442 1262 150329 60966 78827 10536 7713 7713 33903 29850 4053 3540 1436 1856 248 16378 7995 8038 345 DUES AND SUBSCRIPTIONS 2240 908 1175 157 935838 496493 391563 47782 241166 106556 35406 42282 16435 11295 2568 0 5920 525 318544 193055 620039 353713 29207 13215 409490 265204 438697 278419 X 34002 75294 147340 0 181342 75294 620039 353713 -106048 0 X 1 X 0 1 0 X 2395930 1963007 1520127 411062 821252 7111378 2395930 1963007 1520127 411062 821252 7111378 4362760 2748618 10930 9462 11870 14597 6538 53397 7164775 202463 0.38360 0.48280 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 OPERATING LEASE RIGHT-OF-USE ASSET 191875 FINANCE LEASE 1180 193055 REFUNDABLE ADVANCES 72046 FINANCE LEASE OBLIGATION 1180 OPERATING LEASE LIABILITY 191978 265204 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES CLINICAL RESEARCH, IMPLEMENTATION RESEARCH TO ACHIEVE PROOF OF CONCEPT FOR NEW MODELS OF CARE 12320 EUROPE (INCLUDING ICELAND & GREENLAND) 0 1 PROGRAM SERVICES COMMUNICATION CONSULTANT FOR GYNUITY 60140 NORTH AMERICA 0 1 PROGRAM SERVICES CLINICAL RESEARCH, IMPLEMENTATION RESEARCH TO ACHIEVE PROOF OF CONCEPT FOR NEW MODELS OF CARE 47781 0 2 0 0 0 2 120241 0 120241 0 0 0 0 0 0 PART I, LINE 3: THE ORGANIZATION ACCOUNTS FOR EXPENDITURES IN THE LISTED REGIONS USING THE ACCRUAL METHOD OF ACCOUNTING. X X X 0 0 0 0 0 0 0 0 0 BEVERLY WINIKOFF PRESIDENT 170652 0 0 0 0 0 11850 0 1751 0 184253 0 0 0 FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS A FOUNDING MEMBER WHO IS DR. BEVERLY WINIKOFF. FORM 990, PART VI, SECTION A, LINE 7A THE FOUNDING MEMBER SHALL HAVE THE RIGHT TO APPOINT ONE DIRECTOR. FORM 990, PART VI, SECTION A, LINE 7B THE FOLLOWING DECISIONS, IF TAKEN BY THE DIRECTORS, MUST BE APPROVED BY THE FOUNDING MEMBER: AMENDMENT OF THE CERTIFICATE OF INCORPORATION; AMENDMENT OF THE BY-LAWS; MERGER WITH OR ACQUISITION OF ANOTHER ENTITY, SALE OF ALL OR SUBSTANTIALLY ALL OF THE ASSETS OF THE CORPORATION, FILING FOR BANKRUPTCY, OR DISSOLUTION OF THE CORPORATION; ELECTION OR APPOINTMENT OF OFFICERS; HIRING OF AN EXECUTIVE. FORM 990, PART VI, SECTION B, LINE 11B THE COMPLETED IRS FORM 990 IS FIRST SENT TO MANAGEMENT TO REVIEW. UPON COMPLETION OF MANAGEMENT'S REVIEW, THE 990 IS SENT TO THE BOARD OF DIRECTORS FOR REVIEW AND APPROVAL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS REVIEWED AT LEAST ANNUALLY BY THE DIRECTORS. ALL DIRECTORS, OFFICERS AND STAFF ARE REQUIRED TO COMPLETE AND SIGN A CONFLICT OF INTEREST STATEMENT ANNUALLY. A DIRECTOR OR OFFICER WITH A CONFLICT OF INTEREST IS PROHIBITED FROM PARTICIPATING IN DELIBERATIONS AND DECISIONS REGARDING THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 ON AN ANNUAL BASIS, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE SALARY OF THE CEO. IN DETERMINING THE APPROPRIATE SALARY LEVEL, THE BOARD CONSIDERS COMPARABLE COMPENSATION OF CEOS BY REVIEWING AVAILABLE SALARY SURVEYS AND DATA AVAILABLE IN THE 990S OF SIMILAR ORGANIZATIONS. THE COMPENSATION OF TOP MANAGEMENT IS DETERMINED BY THE PRESIDENT OF GYNUITY. SHE REVIEWS COMPENSATION SURVEYS AND VAILABLE COMPENSATION INFORMATION FROM SIMILAR ORGANIZATION IN EFFORT TO KEEP COMPENSATION PROVIDED BY GYNUITY AT AN APPROPRIATE AND COMPETITIVE LEVEL. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G PROGRAM CONSULTANTS: PROGRAM SERVICE EXPENSES 159,029. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 159,029. IRB: PROGRAM SERVICE EXPENSES 4,750. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 4,750. SUB CONTRACTING SERVICES: PROGRAM SERVICE EXPENSES 10,320. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 10,320. PAYROLL PROCESSING: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 3,259. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 3,259.